Kommersiellt obunden läkemedelsinformation riktad till läkare och sjukvårdspersonal

Selegiline

Classification: B

Drug products: Eldepryl®, Emsam, EMSAM, Selegilin Mylan

ATC code: N04BD01

Substances: selegiline, selegiline hydrochloride

Summary

Published controlled studies on differences between men and women regarding the effect of selegline are lacking. Pharmacokinetic studies have not shown any sex differences.
 
The present evidence concerning differences between men and women is limited and do not motivate differentiation in dosing or treatment.

Additional information

Pharmacokinetics and dosing

One review found no sex-related difference in the pharmacokinetics of selegiline following a single oral dose of selegiline 10 mg to six elderly men and six elderly women (age 60-85 years) [1]. No studies with a clinically relevant sex analysis regarding the dosing of selegiline have been found.

Effects

No studies with a clinically relevant sex analysis regarding the effects of selegiline have been found.

Adverse effects

No studies with a clinically relevant sex analysis regarding adverse effects of selegiline have been found.

Reproductive health issues

Regarding teratogenic aspects, please consult the Drugs and Birth Defects Database (in Swedish, Janusmed fosterpåverkan).

Updated: 2019-02-26

Date of litterature search: 2013-04-15

References

  1. Mahmood I. Clinical pharmacokinetics and pharmacodynamics of selegiline An update. Clin Pharmacokinet. 1997;33:91-102. PubMed
  2. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2015 [cited 2016-04-05.] länk

Authors: Linnéa Karlsson Lind, Desirée Loikas

Reviewed by: Expertrådet för neurologiska sjukdomar, Mia von Euler

Approved by: Karin Schenck-Gustafsson